BCMA (TNFRSF17), along with TACI, has recently been demonstrated to be a receptor for BLyS (TNFSF13B
B cell maturation antigen (BCMA, TNFRSF17) is a member of the tumor necrosis factor receptor superfamily that is preferentially expressed in mature B cells.
1-3 BCMA gene was described from the molecular analysis of a t(4;16)(q26;p13.1) chromosome translocation in a human T cell lymphoma. 1 Recently, BCMA, along with transmembrane activator and CAML-interactor (TACI), 4 has been demonstrated to be a receptor for B lymphocyte stimulator (BLyS, also known as BAFF, TALL-1, zTNF4, TNFSF13B), a member of TNF superfamily. [5] [6] [7] [8] BLyS is expressed in monocytes, macrophages, and dendritic cells. [6] [7] [8] [9] BLyS is a potent B cell co-stimulator, and promotes B cell differentiation, proliferation and survival. 6, 7, [10] [11] [12] [13] [14] BLyS activates the transcription factor NF-B by binding to BCMA and TACI, and increases the expression of Bcl-2 that inhibits apoptosis. 4, 10, 13, 15, 16 strated that another member of TNF superfamily, APRIL (a proliferation-inducing ligand), also binds to BCMA. 17 Several lines of evidence indicated that BLyS-BCMA/TACI signaling pathway contributes to the pathogenesis of the autoimmune disease such as systemic lupus erythematosus (SLE). Transgenic mice overexpressing BLyS have been shown to develop autoantibodies, immune complex deposits and symptoms characteristic of SLE. 5, 10, 11 Circulating BLyS is elevated in NZB/W F1 and MRL-lpr/lpr mice during the onset and progression of lupus, 5 and also in human SLE. 18 Moreover, blockade of BLyS signaling was shown to inhibit development of proteinuria in NZB/W F1 mice. 5 On the basis of these observations, we considered BCMA to be a candidate for the susceptibility gene to human autoimmune diseases, such as SLE. Although one single nucleoside polymorphism (SNP) in the 5Ј-untranslated region (UTR), −144CϾT, was previously reported, 19 a systematic variation screening of human BCMA gene has not been reported. In this study, we screened for variations of the human BCMA gene, and detected variations were tested for the association with SLE and rheumatoid arthritis (RA).
Variation screening was carried out for the entire coding region, promoter region (up to nucleotide position −431), and 5Ј and 3ЈUTRs of human BCMA gene, in 10 patients with SLE, 10 patients with RA and 10 healthy individuals. Polymerase chain reaction (PCR)-single strand conformation polymorphism (SSCP) was used for the screening, and nucleotide sequences of the detected variations were determined by direct sequencing. For the detected variation sites, case-control association studies were performed on 160 patients with SLE (male 14, female 146, average age 40.0 years), 205 patients with RA (male 18, female 187, average age 57.8 years) and 224 healthy individuals (male 174, female 100, average age 36.6 years). All patients and controls were unrelated Japanese, living in the Tokyo area. Genotyping was done using PCR-SSCP and PCR-restriction fragment length polymorphism (RFLP).
The human BCMA gene is located on chromosome 16p13.1 and consists of three exons.
1,2 Specific primers were designed based on the genomic sequence (GenBank accession number Z29574). The primer sequences and experimental conditions are listed in Table 1 .
Through the variation screening, two SNPs, (c.477GϾA, c.525GϾA) and one rare variation (c.457GϾA) were detected within the coding region. The designations of the variations are based on references. 20, 21 Among these variations, c.457GϾA was a non-synonymous substitution, which results in the amino acid substitution, A153T. Moreover, two SNPs (−350AϾT, −337TϾC) and two rare variations (−345CϾT, −249TϾC) within the promoter, two SNPs (−150AϾG, −144CϾT) in the 5ЈUTR, one rare variation (c.*11CϾT), one SNP (c.* 206GϾC) and one single nucleotide deletion, (c.*209delT) in the 3ЈUTR, were detected ( Figure 1 ). All variations except −144CϾT have not previously been reported.
We next analyzed the linkage disequilibrium among the detected variations. Positions −350, c.*206 and c.*209 were found to be in positive linkage disequilibrium, and so were positions −337, −150 and c.477. In addition, from the combination of these polymorphisms, it was elucidated that BCMA variations are present as four haplotypes, which account for most of the genotypes in the Japanese population. We designated these haplotypes as BCMA.01, 02, 03 and 04 ( Table 2 ). The haplotype fre- 
The designations of the nucleotide positions are based on references. 20, 21 quencies in healthy controls was 63.2%, 19.4%, 9.4%, and 7.6%, respectively (Table 3) . We next examined whether these haplotypes are associated with the susceptibility to SLE and RA, using the case-control association study. As shown in Table 3 , 40 of 160 patients with SLE (25.0%) possessed BCMA.03 (Table 2) . At this point, it is not known whether this substitution could be associated with change in the expression level of BCMA, or could represent a linkage disequilibrium with other functional polymorphisms. Although the male-to-female ratio was different between patient and control groups, there was no difference in the haplotype frequencies between male and female controls, and therefore adjustment for the gender ratio did not substantially affect the results.
To analyze whether the BCMA haplotypes are associated with a subset of SLE with specific clinical or immunological characteristics of SLE such as age of onset, presence or absence of lupus nephritis, central nervous system disease, serositis, hypocomplementemia, anti-Sm and dsDNA antibodies, the haplotype positivities were compared between the patients with one of these characteristics and healthy individuals. However, no significant difference was observed (data not shown).
Among other variation sites, −144CϾT was observed with a frequency of 1.7%, 2.4% and 3.0% in the healthy individuals, SLE and RA, respectively. Significant difference was not observed among the three groups. Although the haplotype containing −144T cannot be determined due to the low allele frequency and lack of −144T/T homozygotes, all 15 individuals possessing −144T also possessed BCMA.02 haplotype, suggesting that −144T was present in a small proportion of BCMA.02 haplotype.
Other four variations were rare. The only non-synonymous substitution detected in this study, c.457GϾA (A153T), was present in only one patient with RA. Of interest, this patient has a sib affected with RA; however, she was not available for the study. Although it is unlikely that this rare variation is associated with RA at the population level, this amino acid substitution is located in the cytoplasmic region, and it is therefore possible that this substitution may have some effect on the BLyS-BCMA signaling pathway.
In conclusion, we detected several new variations in the coding region, promoter region and UTR of human BCMA gene, and demonstrated the presence of four major haplotypes in human BCMA gene. Human BCMA was shown be conserved with respect to amino acid sequence. Although evidence for significant association with SLE and RA was not detected, a slight tendency for the increase of BCMA.03 in SLE was observed. In the future, the variation screening of human BLyS, TACI and APRIL genes will be of interest to examine the contribution of this pathway to the development of autoimmune diseases.
